A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase III clinical trial designed to evaluate the efficacy and safety of XZP-3287
in combination with Letrozole/Anastrozole versus placebo in combination with
Letrozole/Anastrozole in patients with HR-positive and HER2-negative recurrent/metastatic
breast cancer who have not received systemic anticancer therapy.